TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
DK1656372T3
(da)
|
2003-07-30 |
2013-07-01 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
|
US8211929B2
(en)
|
2004-12-30 |
2012-07-03 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
CN101155800B
(zh)
|
2005-02-04 |
2012-05-23 |
阿斯利康(瑞典)有限公司 |
可用作激酶抑制剂的吡唑基氨基吡啶衍生物
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
KR101312225B1
(ko)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
DK1984357T3
(da)
|
2006-02-17 |
2014-01-13 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
|
CA2642229C
(en)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
KR20090023698A
(ko)
|
2006-06-15 |
2009-03-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
2-아닐리노-4-아미노알킬렌아미노피리미딘
|
US20070293494A1
(en)
*
|
2006-06-15 |
2007-12-20 |
Djung Jane F |
2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
|
TW200817391A
(en)
*
|
2006-06-30 |
2008-04-16 |
Astrazeneca Ab |
Novel compounds
|
US8222256B2
(en)
|
2006-07-05 |
2012-07-17 |
Exelixis, Inc. |
Methods of using IGFIR and ABL kinase modulators
|
DE602007012363D1
(de)
|
2006-10-19 |
2011-03-17 |
Rigel Pharmaceuticals Inc |
2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
|
MX2009004426A
(es)
|
2006-10-23 |
2009-08-12 |
Cephalon Inc |
Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
|
US7803940B2
(en)
|
2006-11-24 |
2010-09-28 |
Takeda Pharmaceutical Company Limited |
Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
|
TW200838559A
(en)
*
|
2006-11-29 |
2008-10-01 |
Imclone Systems Inc |
Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
|
UA100846C2
(uk)
|
2006-12-08 |
2013-02-11 |
Айерем Елелсі |
Сполуки та композиція як інгібітори протеїнкінази
|
CA2671744C
(en)
*
|
2006-12-08 |
2012-08-28 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
US7999006B2
(en)
|
2006-12-14 |
2011-08-16 |
Exelixis, Inc. |
Methods of using MEK inhibitors
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
UA99459C2
(en)
*
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
WO2008135786A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Astrazeneca Ab |
Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
|
JP2010529193A
(ja)
*
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
置換ピラゾール化合物
|
NZ582349A
(en)
|
2007-06-29 |
2012-06-29 |
Sunesis Pharmaceuticals Inc |
Heterocyclic compounds useful as raf kinase inhibitors
|
CL2008001933A1
(es)
|
2007-06-29 |
2009-09-25 |
Millennium Pharm Inc |
Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
|
US8183381B2
(en)
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
WO2009027736A2
(en)
*
|
2007-08-27 |
2009-03-05 |
Astrazeneca Ab |
2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
|
BRPI0815979A2
(pt)
*
|
2007-08-28 |
2017-06-13 |
Irm Llc |
compostos e composições com inibidores de quinase, bem como uso dos mesmos
|
WO2009056886A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Astrazeneca Ab |
Pyrimidine derivatives and their use as modulators of fgfr activity
|
HUE035029T2
(en)
|
2008-05-21 |
2018-03-28 |
Ariad Pharma Inc |
Kinase inhibitor phosphorus derivatives
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
EA020807B1
(ru)
|
2008-06-17 |
2015-01-30 |
Астразенека Аб |
Соединения пиридина
|
JP2011526291A
(ja)
*
|
2008-06-25 |
2011-10-06 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
キナーゼ阻害剤としてのピリミジン誘導体
|
UY31929A
(es)
*
|
2008-06-25 |
2010-01-05 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
US8445505B2
(en)
*
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
TWI546290B
(zh)
*
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
CN102264728B
(zh)
*
|
2008-09-15 |
2015-02-04 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
CN102356075B
(zh)
|
2009-01-23 |
2015-06-10 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
SG173647A1
(en)
|
2009-02-13 |
2011-10-28 |
Shionogi & Co |
Novel triazine derivative and pharmaceutical composition containing same
|
ES2659725T3
(es)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de EGFR y procedimiento de tratamiento de trastornos
|
EP2435422B1
(de)
*
|
2009-05-27 |
2014-12-17 |
AbbVie Inc. |
Pyrimidinhemmer der kinaseaktivität
|
JP2012528175A
(ja)
|
2009-05-27 |
2012-11-12 |
アボット・ラボラトリーズ |
キナーゼ活性のピリミジン阻害剤
|
EP2435435B1
(de)
*
|
2009-05-27 |
2014-01-29 |
AbbVie Inc. |
Pyrimidinhemmer der kinaseaktivität
|
CA2764983A1
(en)
*
|
2009-06-10 |
2010-12-16 |
Abbott Laboratories |
2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
|
WO2011018517A1
(en)
|
2009-08-14 |
2011-02-17 |
Boehringer Ingelheim International Gmbh |
Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
|
US20110053916A1
(en)
|
2009-08-14 |
2011-03-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine compounds as tuberculosis inhibitors
|
US8933227B2
(en)
|
2009-08-14 |
2015-01-13 |
Boehringer Ingelheim International Gmbh |
Selective synthesis of functionalized pyrimidines
|
CN102666553B
(zh)
|
2009-10-01 |
2015-05-06 |
赛马拜制药公司 |
取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
|
EP2519517B1
(de)
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Typ-ii-raf-kinase-hemmer
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
CA2798578C
(en)
|
2010-05-21 |
2015-12-29 |
Chemilia Ab |
Novel pyrimidine derivatives
|
CA2797947C
(en)
|
2010-06-04 |
2019-07-09 |
Charles Baker-Glenn |
Aminopyrimidine derivatives as lrrk2 modulators
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
JP6075621B2
(ja)
|
2010-08-10 |
2017-02-08 |
塩野義製薬株式会社 |
新規複素環誘導体およびそれらを含有する医薬組成物
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
RU2565073C2
(ru)
|
2010-08-10 |
2015-10-20 |
Сионоги Энд Ко., Лтд. |
Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью
|
ES2635713T3
(es)
|
2010-11-01 |
2017-10-04 |
Celgene Car Llc |
Compuestos de heteroarilo y usos de los mismos
|
WO2012061299A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
EP2637502B1
(de)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutanten-selektive egfr-hemmer und verwendungen davon
|
US8815882B2
(en)
*
|
2010-11-10 |
2014-08-26 |
Genentech, Inc. |
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
|
UY33817A
(es)
*
|
2010-12-21 |
2012-07-31 |
Boehringer Ingelheim Int |
?nuevas oxindolpirimidinas bencílicas?.
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
BR112013024378A2
(pt)
|
2011-03-24 |
2016-12-13 |
Chemilia Ab |
novos derivados de pirimidina
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
WO2013026914A1
(en)
*
|
2011-08-25 |
2013-02-28 |
F. Hoffmann-La Roche Ag |
Serine/threonine pak1 inhibitors
|
JP2014532658A
(ja)
|
2011-10-28 |
2014-12-08 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
ブルトン型チロシンキナーゼ疾患または障害を治療する方法
|
EP2776042B1
(de)
|
2011-11-11 |
2019-03-20 |
Duke University |
Wirkstoffkombinationstherapie zur behandlung von soliden tumoren
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
CA2854248A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
2,4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
|
JP6124351B2
(ja)
|
2012-02-09 |
2017-05-10 |
塩野義製薬株式会社 |
複素環および炭素環誘導体
|
GB201204384D0
(en)
*
|
2012-03-13 |
2012-04-25 |
Univ Dundee |
Anti-flammatory agents
|
CA2866857C
(en)
|
2012-03-15 |
2021-03-09 |
Celgene Avilomics Research, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
BR112014022789B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
|
BR112014026952B1
(pt)
*
|
2012-05-03 |
2022-03-15 |
Genentech, Inc |
Derivados de aminopirimidina pirazol e composição que os compreende
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
EP2909194A1
(de)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CA2890018A1
(en)
|
2012-11-05 |
2014-05-08 |
Nant Holdings Ip, Llc |
Substituted indol-5-ol derivatives and their therapeutical applications
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CN103202843B
(zh)
*
|
2012-12-31 |
2015-04-29 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
|
US9145387B2
(en)
|
2013-02-08 |
2015-09-29 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
AU2014233069A1
(en)
|
2013-03-15 |
2015-09-24 |
Nantbioscience, Inc. |
Substituted indol-5-ol derivatives and their therapeutic applications
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
TWI637949B
(zh)
|
2013-06-14 |
2018-10-11 |
塩野義製藥股份有限公司 |
胺基三衍生物及含有其等之醫藥組合物
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
WO2015058140A1
(en)
|
2013-10-18 |
2015-04-23 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CN104926794B
(zh)
*
|
2014-03-17 |
2017-12-05 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
JP6538148B2
(ja)
|
2014-03-28 |
2019-07-03 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されたヘテロアリール化合物および使用方法
|
CN106536503B
(zh)
*
|
2014-04-18 |
2019-09-06 |
北京澳合药物研究院有限公司 |
一种酪氨酸激酶抑制剂及其用途
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2016014551A1
(en)
|
2014-07-21 |
2016-01-28 |
Dana-Farber Cancer Institute, Inc. |
Macrocyclic kinase inhibitors and uses thereof
|
EP3171874B1
(de)
|
2014-07-21 |
2020-11-18 |
Dana-Farber Cancer Institute, Inc. |
Imidazolylkinasehemmer und verwendungen davon
|
JP6624594B2
(ja)
|
2014-08-04 |
2019-12-25 |
ヌエヴォリューション・アクティーゼルスカブNuevolution A/S |
炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体
|
WO2016023014A2
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Uses of salt-inducible kinase (sik) inhibitors
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
CN105461694B
(zh)
*
|
2014-09-27 |
2019-05-24 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
WO2016060963A1
(en)
|
2014-10-14 |
2016-04-21 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
EP3236959A4
(de)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Hemmer der cyclinabhängigen kinase 7 (cdk7)
|
CN104817553B
(zh)
*
|
2015-03-13 |
2018-11-09 |
华东师范大学 |
一种芳香基-杂环取代的嘧啶二胺类化合物及其衍生物及其医药用途
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3307728A4
(de)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Kombinationstherapie von transkriptionshemmern und kinasehemmern
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
WO2017156527A1
(en)
*
|
2016-03-11 |
2017-09-14 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
|
JP6881879B2
(ja)
*
|
2016-04-28 |
2021-06-02 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
Jakキナーゼ阻害剤としてのピリミジン化合物
|
CA3026149A1
(en)
|
2016-06-02 |
2017-12-07 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
PT3472153T
(pt)
|
2016-06-16 |
2021-12-31 |
Denali Therapeutics Inc |
Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
|
EP3481830B1
(de)
|
2016-07-05 |
2022-02-16 |
The Broad Institute, Inc. |
Bicyclische harnstoffkinaseinhibitoren und deren verwendungen
|
JP2019527693A
(ja)
|
2016-08-03 |
2019-10-03 |
サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. |
炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
|
WO2018053373A1
(en)
|
2016-09-16 |
2018-03-22 |
The General Hospital Corporation |
Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
|
JOP20190080A1
(ar)
|
2016-10-14 |
2019-04-11 |
Bayer Pharma AG |
مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
|
US9975886B1
(en)
|
2017-01-23 |
2018-05-22 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
RU2019129727A
(ru)
|
2017-02-28 |
2021-03-30 |
Зэ Дженерал Хоспитал Корпорэйшн |
Применения пиримидопиримидинонов в качестве ингибиторов sik
|
CN111683662B
(zh)
*
|
2017-08-28 |
2024-04-02 |
陈志宏 |
取代嘧啶类化合物及其药物组合物和治疗方法
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
CN111601804A
(zh)
*
|
2018-11-27 |
2020-08-28 |
江苏豪森药业集团有限公司 |
含氮杂芳类衍生物调节剂、其制备方法和应用
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
US11427567B2
(en)
|
2019-08-14 |
2022-08-30 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
KR20220099970A
(ko)
|
2019-10-11 |
2022-07-14 |
인사이트 코포레이션 |
Cdk2 억제제로서의 이환식 아민
|
EP4076657A1
(de)
|
2019-12-20 |
2022-10-26 |
Nuevolution A/S |
Gegen nukleäre rezeptoren wirksame verbindungen
|
CA3174176A1
(en)
|
2020-03-31 |
2021-10-07 |
Sanne Schroder Glad |
Compounds active towards nuclear receptors
|
WO2021198955A1
(en)
|
2020-03-31 |
2021-10-07 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
KR20230074733A
(ko)
*
|
2020-08-26 |
2023-05-31 |
날로 테라퓨틱스 |
Myc 패밀리 원종양유전자 단백질의 조정제
|
CN112225729B
(zh)
*
|
2020-11-04 |
2022-02-01 |
四川大学华西医院 |
嘧啶类衍生物、其制备方法和应用以及药物组合物
|
CN113185428B
(zh)
*
|
2021-05-10 |
2022-07-15 |
安徽省庆云医药股份有限公司 |
一种4-甲基-3-氧代戊腈的合成方法
|
WO2023159307A1
(en)
*
|
2022-02-23 |
2023-08-31 |
Repare Therapeutics Inc. |
Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereof
|
WO2023164612A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Nalo Therapeutics |
Modulators of myc family proto-oncogene protein
|